Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.

MLA

Ni, Jianjiao, et al. “Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-Arm, Phase II Trial.” Radiation Oncology (London, England), vol. 16, no. 1, Sept. 2021, p. 177. EBSCOhost, https://doi.org/10.1186/s13014-021-01905-3.

APA

Ni, J., Zhou, Y., Wu, L., Ai, X., Dong, X., Chu, Q., Han, C., Wang, X., & Zhu, Z. (2021). Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiation Oncology (London, England), 16(1), 177. https://doi.org/10.1186/s13014-021-01905-3

Chicago

Ni, Jianjiao, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Chengbo Han, Xiaofei Wang, and Zhengfei Zhu. 2021. “Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-Arm, Phase II Trial.” Radiation Oncology (London, England) 16 (1): 177. doi:10.1186/s13014-021-01905-3.